Thymidylate synthase inhibitors for non-small cell lung cancer

Bibliography

• Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005;20:476-87
   Google Scholar
• Scagliotti GV, Parikh P, von PJ, Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-51
   PubMed Web of Science ®Google Scholar
• Okamoto I, Yoshioka H, Morita S, Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study. J Clin Oncol 2010;28:5240-6
   PubMed Web of Science ®Google Scholar
• Lehman NL. Future potential of thymidylate synthase inhibitors in cancer therapy. Expert Opin Investig Drugs 2002;11:1775-87
   PubMed Web of Science ®Google Scholar
• Sant M, Aareleid T, Berrino F, EUROCARE-3: survival of cancer patients diagnosed 1990-94–results and commentary. Ann Oncol 2003;14(Suppl 5):v61-118
   PubMed Web of Science ®Google Scholar
• Qiao X, Tullgren O, Lax I, The role of radiotherapy in treatment of stage I non-small cell lung cancer. Lung Cancer 2003;41:1-11
   PubMed Web of Science ®Google Scholar
• Keller SM, Adak S, Wagner H, A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. N Engl J Med 2000;343:1217-22
   PubMed Web of Science ®Google Scholar
• Crino L, Weder W, van MJ, Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl 5):v103-15
   PubMed Web of Science ®Google Scholar
• Marino P, Preatoni A, Cantoni A, Single-agent chemotherapy versus combination chemotherapy in advanced non-small cell lung cancer: a quality and meta-analysis study. Lung Cancer 1995;13:1-12
   PubMed Web of Science ®Google Scholar
• Delbaldo C, Michiels S, Syz N, Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA 2004;292:470-84
   PubMed Web of Science ®Google Scholar
• Ardizzoni A, Boni L, Tiseo M, Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007;99:847-57
   PubMed Web of Science ®Google Scholar
• Schiller JH, Harrington D, Belani CP, Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8
   PubMed Web of Science ®Google Scholar
• D'Addario G, Pintilie M, Leighl NB, Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 2005;23:2926-36
   PubMed Web of Science ®Google Scholar
• Reck M, von PJ, Zatloukal P, Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27:1227-34
   PubMed Web of Science ®Google Scholar
• Gutierrez ME, Kummar S, Giaccone G. Next generation oncology drug development: opportunities and challenges. Nat Rev Clin Oncol 2009;6:259-65
   PubMed Web of Science ®Google Scholar
• Pirker R, Pereira JR, Szczesna A, Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009;373:1525-31
   PubMed Web of Science ®Google Scholar
• Fojo T, Grady C. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst 2009;101:1044-8
   PubMed Web of Science ®Google Scholar
• Ku GY, Haaland BA, de Lima LG. Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of phase III trials. Lung Cancer 2011 May 10. [Epub ahead of print]
   Google Scholar
• Azzoli CG, Baker S Jr, Temin S, American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009;27:6251-66
   PubMed Web of Science ®Google Scholar
• Arango BA, Castrellon AB, Santos ES, Second-line therapy for non-small-cell lung cancer. Clin Lung Cancer 2009;10:91-8
   PubMed Web of Science ®Google Scholar
• Fossella FV, Lee JS, Shin DM, Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol 1995;13:645-51
   PubMed Web of Science ®Google Scholar
• Hanna N, Shepherd FA, Fossella FV, Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-97
   PubMed Web of Science ®Google Scholar
• Reck M, Mok T, Wolf J, Reviewing the safety of erlotinib in non-small cell lung cancer. Expert Opin Drug Saf 2011;10:147-57
   PubMed Web of Science ®Google Scholar
• Gridelli C, Maione P, Rossi A, New avenues for second-line treatment of metastatic non-small-cell lung cancer. Expert Rev Anticancer Ther 2009;9:115-24
   PubMed Web of Science ®Google Scholar
• Carreras CW, Santi DV. The catalytic mechanism and structure of thymidylate synthase. Annu Rev Biochem 1995;64:721-62
   PubMed Web of Science ®Google Scholar
• Rahman L, Voeller D, Rahman M, Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme. Cancer Cell 2004;5:341-51
   PubMed Web of Science ®Google Scholar
• Chen M, Rahman L, Voeller D, Transgenic expression of human thymidylate synthase accelerates the development of hyperplasia and tumors in the endocrine pancreas. Oncogene 2007;26:4817-24
   PubMed Web of Science ®Google Scholar
• Muggia FM, Peters GJ, Landolph JR. XIII International Charles Heidelberger Symposium and 50 Years of Fluoropyrimidines in Cancer Therapy Held on september 6 to 8, 2007 at New York University Cancer Institute, Smilow Conference Center. Mol Cancer Ther 2009;8:992-9
   PubMedGoogle Scholar
• Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003;3:330-8
   PubMed Web of Science ®Google Scholar
• Ju J, Pedersen-Lane J, Maley F, Regulation of p53 expression by thymidylate synthase. Proc Natl Acad Sci USA 1999;96:3769-74
   PubMed Web of Science ®Google Scholar
• Chu E, Takechi T, Jones KL, Thymidylate synthase binds to c-myc RNA in human colon cancer cells and in vitro. Mol Cell Biol 1995;15:179-85
   PubMed Web of Science ®Google Scholar
• Giovannetti E, Backus HH, Wouters D, Functional inactivity and mutations of p53 differentially affect sensitivity to 5-fluorouracil and antifolate inhibitors of thymidylate synthase (TS) by altering TS levels in colorectal cancer cells. Nucleosides Nucleotides Nucleic Acids 2008;27:740-5
   PubMed Web of Science ®Google Scholar
• DeGregori J, Kowalik T, Nevins JR. Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G1/S-regulatory genes. Mol Cell Biol 1995;15:4215-24
   PubMed Web of Science ®Google Scholar
• Chu E, Voeller D, Koeller DM, Identification of an RNA binding site for human thymidylate synthase. Proc Natl Acad Sci USA 1993;90:517-21
   PubMed Web of Science ®Google Scholar
• Lin X, Parsels LA, Voeller DM, Characterization of a cis-acting regulatory element in the protein coding region of thymidylate synthase mRNA. Nucleic Acids Res 2000;28:1381-9
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yang S, Liu M, Interaction between thymidylate synthase and its cognate mRNA in zebrafish embryos. PLoS One 2010;5:e10618
   Google Scholar
• Kitchens ME, Forsthoefel AM, Rafique Z, Ligand-mediated induction of thymidylate synthase occurs by enzyme stabilization. Implications for autoregulation of translation. J Biol Chem 1999;274:12544-7
   PubMed Web of Science ®Google Scholar
• Chattopadhyay S, Moran RG, Goldman ID. Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther 2007;6:404-17
   PubMed Web of Science ®Google Scholar
• Vogelzang NJ, Rusthoven JJ, Symanowski J, Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-44
   PubMed Web of Science ®Google Scholar
• Gronberg BH, Bremnes RM, Flotten O, Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2009;27:3217-24
   PubMed Web of Science ®Google Scholar
• Scagliotti G, Hanna N, Fossella F, The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009;14:253-63
   PubMed Web of Science ®Google Scholar
• Ciuleanu T, Brodowicz T, Zielinski C, Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009;374:1432-40
   PubMed Web of Science ®Google Scholar
• Paz-Ares LG, De Marinis F, Dediu M, PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC). J Clin Oncol 2011;29(Suppl):abstract CRA7510
   Google Scholar
• Ceppi P, Volante M, Saviozzi S, Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006;107:1589-96
   PubMed Web of Science ®Google Scholar
• Shih C, Chen VJ, Gossett LS, LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997;57:1116-23
   PubMed Web of Science ®Google Scholar
• Chen VJ, Bewley JR, Andis SL, Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells. Br J Cancer 1998;78(Suppl 3):27-34
   PubMedGoogle Scholar
• Takimoto CH. New antifolates: pharmacology and clinical applications. Oncologist 1996;1:68-81
   PubMedGoogle Scholar
• Giovannetti E, Mey V, Nannizzi S, Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 2005;68:110-18
   PubMed Web of Science ®Google Scholar
• Giovannetti E, Lemos C, Tekle C, Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells. Mol Pharmacol 2008;73:1290-300
   PubMed Web of Science ®Google Scholar
• Takezawa K, Okamoto I, Okamoto W, Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer. Br J Cancer 2011;104:1594-601
   PubMed Web of Science ®Google Scholar
• Hanauske AR, Eismann U, Oberschmidt O, In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression. Invest New Drugs 2007;25:417-23
   PubMed Web of Science ®Google Scholar
• Gomez HL, Santillana SL, Vallejos CS, A phase II trial of pemetrexed in advanced breast cancer: clinical response and association with molecular target expression. Clin Cancer Res 2006;12:832-8
   PubMed Web of Science ®Google Scholar
• Righi L, Papotti MG, Ceppi P, Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. J Clin Oncol 2010;28:1534-9
   PubMed Web of Science ®Google Scholar
• Zucali PA, Giovannetti E, Destro A, Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin. Clin Cancer Res 2011;17:2581-90
   PubMed Web of Science ®Google Scholar
• Chen CY, Chang YL, Shih JY, Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed. Lung Cancer 2011; [Epub ahead of print]
   Web of Science ®Google Scholar
• Sun JM, Han J, Ahn JS, Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy. J Thorac Oncol 2011; [Epub ahead of print]
   Google Scholar
• Higashiyama M, Kodama K, Yokouchi H, Thymidylate synthase and dihydropyrimidine dehydrogenase activities in non-small cell lung cancer tissues: relationship with in vitro sensitivity to 5-fluorouracil. Lung Cancer 2001;34:407-16
   PubMed Web of Science ®Google Scholar
• Nakagawa T, Tanaka F, Otake Y, Prognostic value of thymidylate synthase expression in patients with p-stage I adenocarcinoma of the lung. Lung Cancer 2002;35:165-70
   PubMed Web of Science ®Google Scholar
• Zheng Z, Li X, Schell MJ, Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer. Cancer 2008;112:2765-73
   PubMed Web of Science ®Google Scholar
• Edler D, Kressner U, Ragnhammar P, Immunohistochemically detected thymidylate synthase in colorectal cancer: an independent prognostic factor of survival. Clin Cancer Res 2000;6:488-92
   PubMed Web of Science ®Google Scholar
• Novello S, Scagliotti G, Torri V, International tailored chemotherapy adjuvant trial: ITACA trial. J Clin Oncol 2011;29(Suppl):abstract e17514
   Google Scholar
• Assaraf YG. Molecular basis of antifolate resistance. Cancer Metastasis Rev 2007;26:153-81
   PubMed Web of Science ®Google Scholar
• Uemura T, Oguri T, Ozasa H, ABCC11/MRP8 confers pemetrexed resistance in lung cancer. Cancer Sci 2010;101:2404-10
   PubMed Web of Science ®Google Scholar
• Assaraf YG. The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis. Drug Resist Updat 2006;9:227-46
   PubMed Web of Science ®Google Scholar
• Liani E, Rothem L, Bunni MA, Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Int J Cancer 2003;103:587-99
   PubMed Web of Science ®Google Scholar
• Zhao R, Titus S, Gao F, Molecular analysis of murine leukemia cell lines resistant to 5, 10-dideazatetrahydrofolate identifies several amino acids critical to the function of folylpolyglutamate synthetase. J Biol Chem 2000;275:26599-606
   PubMed Web of Science ®Google Scholar
• Pizzorno G, Moroson BA, Cashmore AR, Multifactorial resistance to 5,10-dideazatetrahydrofolic acid in cell lines derived from human lymphoblastic leukemia CCRF-CEM. Cancer Res 1995;55:566-73
   PubMed Web of Science ®Google Scholar
• Stark M, Wichman C, Avivi I, Aberrant splicing of folylpolyglutamate synthetase as a novel mechanism of antifolate resistance in leukemia. Blood 2009;113:4362-9
   PubMed Web of Science ®Google Scholar
• Zhao R, Gao F, Goldman ID. Marked suppression of the activity of some, but not all, antifolate compounds by augmentation of folate cofactor pools within tumor cells. Biochem Pharmacol 2001;61:857-65
   PubMed Web of Science ®Google Scholar
• Zhao R, Zhang S, Hanscom M, Loss of reduced folate carrier function and folate depletion result in enhanced pemetrexed inhibition of purine synthesis. Clin Cancer Res 2005;11:1294-301
   PubMedGoogle Scholar
• Chattopadhyay S, Zhao R, Krupenko SA, The inverse relationship between reduced folate carrier function and pemetrexed activity in a human colon cancer cell line. Mol Cancer Ther 2006;5:438-49
   PubMed Web of Science ®Google Scholar
• Matherly LH, Goldman DI. Membrane transport of folates. Vitam Horm 2003;66:403-56
   PubMed Web of Science ®Google Scholar
• Gorlick R, Goker E, Trippett T, Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. Blood 1997;89:1013-18
   PubMed Web of Science ®Google Scholar
• Zhao R, Gao F, Hanscom M, A prominent low-pH methotrexate transport activity in human solid tumors: contribution to the preservation of methotrexate pharmacologic activity in HeLa cells lacking the reduced folate carrier. Clin Cancer Res 2004;10:718-27
   PubMed Web of Science ®Google Scholar
• Zhao R, Qiu A, Tsai E, The proton-coupled folate transporter: impact on pemetrexed transport and on antifolates activities compared with the reduced folate carrier. Mol Pharmacol 2008;74:854-62
   PubMed Web of Science ®Google Scholar
• Gonen N, Bram EE, Assaraf YG. PCFT/SLC46A1 promoter methylation and restoration of gene expression in human leukemia cells. Biochem Biophys Res Commun 2008;376:787-92
   PubMed Web of Science ®Google Scholar
• Diop-Bove NK, Wu J, Zhao R, Hypermethylation of the human proton-coupled folate transporter (SLC46A1) minimal transcriptional regulatory region in an antifolate-resistant HeLa cell line. Mol Cancer Ther 2009;8:2424-31
   PubMed Web of Science ®Google Scholar
• Ansfield FJ, Kallas GJ, Singson JP. Phase I-II studies of oral tegafur (ftorafur). J Clin Oncol 1983;1:107-10
   PubMed Web of Science ®Google Scholar
• Keicho N, Saijo N, Shinkai T, Phase II study of UFT in patients with advanced non-small cell lung cancer. Jpn J Clin Oncol 1986;16:143-6
   PubMed Web of Science ®Google Scholar
• Shirasaka T, Shimamato Y, Ohshimo H, Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996;7:548-57
   PubMed Web of Science ®Google Scholar
• Tanaka F, Wada H, Fukushima M. UFT and S-1 for treatment of primary lung cancer. Gen Thorac Cardiovasc Surg 2010;58:3-13
   PubMedGoogle Scholar
• Surmont V, Aerts JG, Pouw E, Oral UFT, etoposide and leucovorin in recurrent non-small cell lung cancer: a non-randomized phase II study. Lung Cancer 2009;66:333-7
   PubMed Web of Science ®Google Scholar
• Sandler A, Graham C, Baggstrom M, An open-label, multicenter, three-stage, phase ii study of S-1 in combination with cisplatin as first-line therapy for patients with advanced non-small cell lung cancer. J Thorac Oncol 2011; Epub ahead of print
   Google Scholar
• Okabe T, Okamoto I, Tsukioka S, Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase. Mol Cancer Ther 2008;7:599-606
   PubMed Web of Science ®Google Scholar
• Okabe T, Okamoto I, Tsukioka S, Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification. Clin Cancer Res 2009;15:907-13
   PubMed Web of Science ®Google Scholar
• Takeda M, Okamoto I, Hirabayashi N, Thymidylate synthase and dihydropyrimidine dehydrogenase expression levels are associated with response to S-1 plus carboplatin in advanced non-small cell lung cancer. Lung Cancer 2011;73:103-9
   PubMed Web of Science ®Google Scholar
• Yamamoto N, Yamanaka T, Ichinose Y, Pooled analysis of S-1 trials in non-small cell lung cancer according to histological type. Anticancer Res 2010;30:2985-90
   PubMed Web of Science ®Google Scholar
• Manegold C, Buchholz E, Kloeppel R, Phase I dose-escalating study of raltitrexed ('Tomudex') and cisplatin in metastatic non-small cell lung cancer. Lung Cancer 2002;36:183-9
   PubMed Web of Science ®Google Scholar
• Mendiola C, Vaz MA. Is capecitabine a new choice of treatment for lung adenocarcinoma? A case report involving partial response in second line of treatment and hypothesis of the biological basis. Clin Transl Oncol 2009;11:554-7
   PubMed Web of Science ®Google Scholar
• Han JY, Hong EK, Lee SY, Thymidine phosphorylase expression in tumour cells and tumour response to capecitabine plus docetaxel chemotherapy in non-small cell lung cancer. J Clin Pathol 2005;58:650-4
   PubMed Web of Science ®Google Scholar
• Ko JC, Tsai MS, Kuo YH, Modulation of Rad51, ERCC1, and thymidine phosphorylase by emodin result in synergistic cytotoxic effect in combination with capecitabine. Biochem Pharmacol 2011;81:680-90
   PubMed Web of Science ®Google Scholar
• Kindwall-Keller T, Otterson GA, Young D, Phase II evaluation of docetaxel-modulated capecitabine in previously treated patients with non-small cell lung cancer. Clin.Cancer Res 2005;11:1870-6
   PubMed Web of Science ®Google Scholar
• Giovannetti E, Zucali PA, Peters GJ, Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib. Mol Cancer Ther 2010;9:581-93
   PubMed Web of Science ®Google Scholar
• Mandola MV, Stoehlmacher J, Muller-Weeks S, A novel single nucleotide polymorphism within the 5' tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 2003;63:2898-904
   PubMed Web of Science ®Google Scholar
• Horie N, Aiba H, Oguro K, Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5'-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 1995;20:191-7
   PubMed Web of Science ®Google Scholar
• Smit EF, Burgers SA, Biesma B, Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol 2009;27:2038-45
   PubMed Web of Science ®Google Scholar
• Adjei AA, Mandrekar SJ, Dy GK, Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426. J Clin Oncol 2010;28:614-19
   PubMed Web of Science ®Google Scholar
• Wynes MW, Dziadziuszko R, Singh S, Thymidylate synthase (TS) gene copy number in NSCLC. J Clin Oncol 2010;28(Suppl):abstract e21063
   Google Scholar
• Boni V, Bitarte N, Cristobal I, miR-192/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidilate synthase regulation. Mol Cancer Ther 2010;9:2265-75
   PubMed Web of Science ®Google Scholar
• Giovannetti E, Erozenci A, Smit J, Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. Crit Rev Oncol Hematol 2011; [Epub ahead of print]
   Web of Science ®Google Scholar
• Li T, Ling YH, Goldman ID, Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells. Clin Cancer Res 2007;13:3413-22
   PubMed Web of Science ®Google Scholar
• Takezawa K, Okamoto I, Tanizaki J, Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor. Mol Cancer Ther 2010;9:1647-56
   PubMed Web of Science ®Google Scholar
• Tekle C, Giovannetti E, Sigmond J, Molecular pathways involved in the synergistic interaction of the PKC beta inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells. Br J Cancer 2008;99:750-9
   PubMed Web of Science ®Google Scholar
• Ceppi P, Rapa I, Lo IM, Expression and pharmacological inhibition of thymidilate synthase and Src kinase in non-small cell lung cancer. Int J Cancer 2011; [Epub ahead of print]
   Google Scholar
• Hanauske AR, Lahn M, Musib LC, Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer. Ann Oncol 2009;20:1565-75
   PubMed Web of Science ®Google Scholar
• Giovannetti E, Honeywell R, Hanauske AR, Pharmacological aspects of the enzastaurin-pemetrexed combination in non-small cell lung cancer (NSCLC). Curr Drug Targets 2010;11:12-28
   PubMed Web of Science ®Google Scholar
• Ota K, Taguchi T, Kimura K. Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol 1988;22(4):333-8
   PubMed Web of Science ®Google Scholar